Unilife Alan Shortall - Unilife Alan Shortall
The Founder, CEO and Executive Director of Unilife is Alan Shortall. Unilife Corporation is a U.S. based developer and manufacturer of a diversified portfolio of advanced drug delivery systems. Since the 2002 founding of Unilife, Alan Shortall has been the principal driver of the company’s rapid business expansion, the commercialization of its diversified and rapidly growing proprietary portfolio of advanced drug delivery devices and the development of strong relationships with a number of top tier pharmaceutical companies.
As the leader of Unilife, Alan Shortall is driving the expansion of the company and the delivery of key business milestones to not only create strong shareholder value, but enhance and save the lives of millions of people worldwide at risk of harm from unsafe injection practices.
Before establishing Unilife, Alan Shortall has lived a lived a full life that established his capabilities as a skilled entrepreneur. Alan Shortall was born in Dublin, Ireland to a family of six children. He found his calling to the world of business and commerce at a young age. Laying the foundation for the leadership and stamina that would be required to successfully spearhead the growth of Unilife, Alan Shortall established his own business development company specializing in marketing consultancy services for public and private organizations in 1982. In this role, Alan Shortall successfully guided the international launch of multi-million dollar consumer brands such as West Coast Cooler.
In 1989, Alan Shortall migrated to Australia and became an Australian citizen. There, Alan Shortall established a successful business consultancy group that co-coordinated a series of commercial projects within the retail, consumer goods, IT, insurance and banking sectors.
Alan Shortall was in retirement in 2001 when approached by inventors Craig Thorley and Joe Kaal to support the commercialization of revolutionary safety syringe technology they had developed. Together with Thorley, Kaal and other initial investors, Alan Shortall listed Unilife (then known as Unitract) on the Australian Stock Exchange in November 2002. At that time, in addition to Alan Shortall, Unilife employed only three people (including Thorley and Kaal) operating out of a small micro-office in Sydney.
Since then, the expansion of Unilife under Alan Shortall has progressively occurred to the point where it is now a fast-growing and emerging global leader for advanced drug delivery systems. Alan Shortall led Unilife in the development and patent protection of its safety syringe technology from core IP design through to the final production and commercialization of regulatory approved products. In addition, Alan Shortall guided Unilife in the diversification of its safety syringes technology from one technology concept into a full diversified portfolio of clinical and prefilled syringes, as well as other advanced drug delivery systems that can be used with countless injectable drugs and vaccines. In building a relationship with Sanofi since 2003 on behalf of Unilife, Alan Shortall represented the Company in all negotiations. These discussions by Alan Shortall led Unilife to sign an exclusive agreement in 2008 for the exclusive right to purchase and commercialization of the Unifill ready to fill syringe. The Unifill syringe is the world’s first and only prefilled syringe with integrated safety features within the glass barrel. On behalf of Unilife, Alan Shortall has also been instrumental in attracting world-class experts from the pharmaceutical and medical device industries to the Board and executive management team. Working alongside Alan Shortall at Unilife are respected executives including COO Dr. Ramin Mojdeh, CFO Rich Wieland, VP Strategic Marketing Jack Kelley and VP Commercial Development Michael Ratigan. Joining Alan Shortall on Unilife’s Board of Directors are Mr Jim Bosnjak (Chairman), Marc Firestone, Mary Kate Wold, John Lund, Jeff Carter and Bill Galle.
In 2006, Alan Shortall led Unilife in its acquisition of Integrated BioSciences Inc,(IBS), a US contract medical device manufacturer. This resulted in Alan Shortall merging Unilife together with IBS in 2009 resulting in Unilife becoming a U.S. based business.
Between 2008 and 2010, Alan Shortall spearheaded Unilife’s transition from Australia to a fully based and registered United States business. This included the redomiciliation by Alan Shortall of Unilife into a Delaware registered Company, and its listing on the NASDAQ stock exchange (NASDAQ:UNIS) in February 2010. Unilife also continues to trade on the Australian Stock Exchange (UNS:ASX).
At Unilife, Alan Shortall is today joined by 150 staff and associates located at its headquarters and state-of-the-art manufacturing facility in York, Pennsylvania. Operating in partnership with the Board and executive management team at Unilife, Alan Shortall is currently responsible for the development of the Company in the U.S. and on a global basis.
In recognition of his substantial marketing and commercial experience and solid leadership of Unilife, Alan Shortall was named as one of 100 Notable People in the medical device industry by trade magazine Medical Device and Diagnostic Industry (MD&DI) in 2008. In January 2010 in recognition of his work in driving the commercialization of the Unifill syringe, the leading product at Unilife, Alan Shortall was profiled on the front cover of Drug Delivery Technology magazine.
In September 2008, to support the continued growth and international expansion of Unilife, Alan Shortall relocated to Pennsylvania where he currently resides with his wife, artist Lynda Shortall. He has five children, including four from a previous marriage. Prior to the founding of Unilife, Alan Shortall represented Australia in the World Championships of Practical Pistol Shooting for seven years during the 1990s, winning team silver and bronze in the World Championships. He has competed at the highest level in a number of sports including Martial Arts, Motor Sports, Equestrian, Triathlon and Ice Hockey.